Quantcast

Latest Bevacizumab Stories

2014-07-12 23:02:37

ResearchMoz presents this most up-to-date research on Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market. View All Therapeutic Area Market Research Reports at http://www.researchmoz.us/therapeutic-area-market-reports-37.html. Albany, NY (PRWEB) July 12, 2014 “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive...

2014-06-30 13:06:13

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies,"...

2014-06-30 12:40:20

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs --bevacizumab and cetuximab-- and the study...

2014-06-26 12:27:15

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Colorectal Cancer -- KOL Insight Modulehttp://www.reportbuyer.com/pharma_healthcare/diseases/colorectal_cancer_kol_insight_module.html IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader...

2014-06-18 23:02:56

New research report “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, in 2019, the world GBM market value is anticipated to amount to USD 583 million. London, UK (PRWEB) June 18, 2014 Owing to the poor prognosis under presently available treatment options, therapies with high...

2014-06-13 08:23:58

Analysis of PRiDe, a U.S. commercial registry of 457 recurrent glioblastoma patients, demonstrates that patients treated with NovoTTF Therapy at their first recurrence achieved a median overall survival of 20 months NEW YORK, June 13, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that subgroup survival data from its U.S. commercial patient registry will be presented at the 16(th) Biennial Canadian Neuro-Oncology Meeting in Halifax, Nova Scotia,...

2014-06-11 08:29:11

INDIANAPOLIS, June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Phase III REACH trial of CYRAMZA(TM) (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant. Encouraging single-agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints of progression-free survival, overall...

2014-06-10 16:27:04

INCLINE VILLAGE, Nev., June 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2014, of approximately $140 million, as compared with actual revenue of $143.6 million for the second quarter of 2013, an approximate 3 percent decrease. The forecasted revenues are driven by increased first quarter 2014 sales for Avastin(®), Herceptin(®), Xolair(®), Kadcyla(®), Perjeta(®) and Actemra(®) for which PDL...

2014-06-05 12:28:09

Two New Therapies Will Match Progression-Free Survival Improvements Required By Surveyed U.S. Payers for Formulary Inclusion, According to a New Report from Decision Resources Group BURLINGTON, Mass., June 5, 2014 /PRNewswire/ -- Decision Resources Group finds that in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO). MOS and disease progression are also key...

2014-06-03 23:08:44

ResearchMoz.us include new market research report "Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs" to its huge collection of research reports. Albany, NY (PRWEB) June 03, 2014 "Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs", which provides in-depth analysis of breast...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'